DK141773B - Fremgangsmåde til fremstilling af et antitumormiddel. - Google Patents
Fremgangsmåde til fremstilling af et antitumormiddel. Download PDFInfo
- Publication number
- DK141773B DK141773B DK422475AA DK422475A DK141773B DK 141773 B DK141773 B DK 141773B DK 422475A A DK422475A A DK 422475AA DK 422475 A DK422475 A DK 422475A DK 141773 B DK141773 B DK 141773B
- Authority
- DK
- Denmark
- Prior art keywords
- tumor
- cytotoxic agent
- chloroethyl
- immunoglobulin
- agent
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title description 10
- 238000004519 manufacturing process Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 description 27
- 229940127089 cytotoxic agent Drugs 0.000 description 27
- 239000002254 cytotoxic agent Substances 0.000 description 27
- 231100000599 cytotoxic agent Toxicity 0.000 description 26
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 4
- HWAVIYAFGOQVNJ-UHFFFAOYSA-N 4-n,4-n-bis(2-chloroethyl)benzene-1,4-diamine Chemical compound NC1=CC=C(N(CCCl)CCCl)C=C1 HWAVIYAFGOQVNJ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- -1 phenyl diamines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- SNFZPEZEZZWYMP-UHFFFAOYSA-N [4-[bis(2-chloroethyl)amino]phenyl]azanium;chloride Chemical compound Cl.NC1=CC=C(N(CCCl)CCCl)C=C1 SNFZPEZEZZWYMP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GBCKRQRXNXQQPW-UHFFFAOYSA-N n,n-dimethylprop-2-en-1-amine Chemical group CN(C)CC=C GBCKRQRXNXQQPW-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Metal Rolling (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB41037/74A GB1509707A (en) | 1974-09-20 | 1974-09-20 | Immunological compounds |
| GB4103774 | 1974-09-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK422475A DK422475A (enrdf_load_stackoverflow) | 1976-03-21 |
| DK141773B true DK141773B (da) | 1980-06-16 |
| DK141773C DK141773C (enrdf_load_stackoverflow) | 1980-11-03 |
Family
ID=10417824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK422475AA DK141773B (da) | 1974-09-20 | 1975-09-19 | Fremgangsmåde til fremstilling af et antitumormiddel. |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS5161640A (enrdf_load_stackoverflow) |
| DE (1) | DE2541931A1 (enrdf_load_stackoverflow) |
| DK (1) | DK141773B (enrdf_load_stackoverflow) |
| FR (1) | FR2285145A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1509707A (enrdf_load_stackoverflow) |
| NL (1) | NL7511089A (enrdf_load_stackoverflow) |
| SE (1) | SE7510505L (enrdf_load_stackoverflow) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4067971A (en) * | 1976-05-13 | 1978-01-10 | The Procter & Gamble Company | Therapeutic composition |
| JPS54132503A (en) * | 1978-04-07 | 1979-10-15 | Kayaku Antibiotic Research Co | Immune globulin combined neocarcinostatin |
| JPS5592325A (en) * | 1978-12-29 | 1980-07-12 | Kureha Chem Ind Co Ltd | Antitumor agent and its preparation |
| JPS5665828A (en) * | 1979-11-02 | 1981-06-03 | Kureha Chem Ind Co Ltd | Antitumor agent |
| JPS5665829A (en) * | 1979-11-02 | 1981-06-03 | Kureha Chem Ind Co Ltd | Antitumor agent |
| US4315851A (en) | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| DE3167679D1 (en) * | 1980-03-31 | 1985-01-24 | Inst Int Pathologie Cellulaire | Pharmaceutical forms, their preparation and compositions containing the same |
| JPS58118520A (ja) * | 1982-01-09 | 1983-07-14 | Hidematsu Hirai | 抗腫瘍性蛋白複合体およびその製造法 |
| JPS59186924A (ja) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| DE3513572A1 (de) * | 1985-04-16 | 1986-10-16 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion |
| JPS62228025A (ja) * | 1985-12-27 | 1987-10-06 | Teijin Ltd | 抗体複合体の製造方法 |
| WO1988007553A1 (en) * | 1987-03-26 | 1988-10-06 | Teijin Limited | Process for preparing antibody complex |
| US5773435A (en) * | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| AU649275B2 (en) * | 1990-11-06 | 1994-05-19 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
| DE4122210C2 (de) * | 1991-07-04 | 1999-04-01 | Deutsches Krebsforsch | Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung |
-
1974
- 1974-09-20 GB GB41037/74A patent/GB1509707A/en not_active Expired
-
1975
- 1975-09-19 FR FR7528837A patent/FR2285145A1/fr active Granted
- 1975-09-19 JP JP50113541A patent/JPS5161640A/ja active Pending
- 1975-09-19 DK DK422475AA patent/DK141773B/da unknown
- 1975-09-19 SE SE7510505A patent/SE7510505L/xx unknown
- 1975-09-19 NL NL7511089A patent/NL7511089A/xx not_active Application Discontinuation
- 1975-09-19 DE DE19752541931 patent/DE2541931A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2285145B1 (enrdf_load_stackoverflow) | 1980-05-30 |
| SE7510505L (sv) | 1976-03-22 |
| FR2285145A1 (fr) | 1976-04-16 |
| DK141773C (enrdf_load_stackoverflow) | 1980-11-03 |
| GB1509707A (en) | 1978-05-04 |
| JPS5161640A (en) | 1976-05-28 |
| DK422475A (enrdf_load_stackoverflow) | 1976-03-21 |
| NL7511089A (nl) | 1976-03-23 |
| DE2541931A1 (de) | 1976-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220387314A1 (en) | Albumin-pd-1 paclitaxel nanoparticle complex compositions and methods of making and using the same | |
| US10780049B2 (en) | Lyophilized compositions comprising albumin-rankl or albumin-GD2 paclitaxel nanoparticle complexes | |
| DK141773B (da) | Fremgangsmåde til fremstilling af et antitumormiddel. | |
| EP3506942B1 (en) | Carrier-pd-l1 binding agent compositions for treating cancers | |
| ES2266041T3 (es) | Proteina serica y celular de anclaje y conjugados. | |
| DE69416116T2 (de) | Effektorenhaltige mittel mit verlängerter zirkulationsdauer sowie verfahren | |
| US4263279A (en) | Pharmaceutically active compositions containing adriamycin and daunomycin | |
| JPH05504554A (ja) | 免疫強化を促進するための方法と組成物 | |
| JPH02503088A (ja) | 抗体フラグメント複合体の調製方法 | |
| CS235525B2 (en) | Method of conjugate preparation containing immunoglobulin or immunoglobulin's fragment | |
| US4017471A (en) | Immunological compounds | |
| Agodoa et al. | Precipitating antigen-antibody systems are required for the formation of subepithelial electron-dense immune deposits in rat glomeruli. | |
| FI98706C (fi) | Menetelmä terapeuttisesti käyttökelpoisen immunoglobuliinikonjugaatin valmistamiseksi | |
| JPH0640945A (ja) | Ｆｃフラグメント結合抗腫瘍剤 | |
| JPH062679B2 (ja) | 免疫毒素製剤 | |
| JPH0641423B2 (ja) | 細胞毒性薬剤組成物及び細胞毒性薬剤キット | |
| JP2003513985A (ja) | 天然に存在しないエナンチオマー（Ｌ−ビオチン）を結合する抗体および該抗体のターゲッティング薬剤（ａｇｅｎｔ）としての使用 | |
| La Via et al. | Studies on Fc receptor function: I. IgG-mediated inhibition of B lymphocyte activation by T-dependent and T-independent antigens | |
| AU619195B2 (en) | Hepatic blocking agents | |
| US5151266A (en) | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies | |
| Woodman | Localized incorporation of iododeoxyuridine from polycation-complexed iododeoxycytidylic acid into DNA of several murine and hamster tumors | |
| EP0213881B1 (en) | The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies | |
| CA1050012A (en) | Conjugates of anti-cancer drugs with antibodies | |
| Das et al. | Correlation between antitumor activity of protein A and in vivo formation of defined high molecular weight complexes with immunoglobulin G in BALB/c mice | |
| Arnon et al. | Antibodies as carriers for oncostatic materials |